Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Four-month Short Course Regimen in Low Risk Active Tuberculosis
NCT06727864Phase 3Recruiting
- Sponsor
- Kaohsiung Veterans General Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isoniazid, rifampicin, pyrazinamide and ethambutol in pulmonary tuberculosis (TB) (2 arms), sponsored by Kaohsiung Veterans General Hospital. Primary endpoints: TB disease free survival at 12 months and Grade 3-5 adverse events at 6 months. Started Jan 2024; status: recruiting.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06727864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727864.